Enterolactone promotes efficacy of gemcitabine on epithelial ovarian cancer and ameliorates gut dysbacteriosis
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.70241 ↗At a glance
Journal article in British Journal of Pharmacology, 2026. Written by Danli Cao and 19 co-authors. Institution: Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, State-Province Key Laboratory of Biomedicin…. Major MEDLINE topics: Carcinoma, Ovarian Epithelial, Deoxycytidine, 4-Butyrolactone, Ovarian Neoplasms. 59 references. Funded by: Heilongjiang Postdoctoral Financial Assistance, Merit-based Funding for Returned Overseas Students in Heilongjiang Province, the National Natural Science Foundation of China.
Abstract (original language)
Background and Purpose The effectiveness of conventional treatments for epithelial ovarian cancer (EOC) is very limited and their side effects are serious. Previous research has demonstrated the inhibitory effects of enterolactone (ENL) on EOC by inhibiting malignant angiogenesis. Gemcitabine (Gem) is a chemotherapeutic agent commonly used for the treatment of EOC with limited efficacy. In this study, we aimed to explore the combined inhibitory effects of ENL and Gem on EOC. Experimental approach We detected the proliferation ability of EOC cells after ENL/Gem/ENL + Gem by CCK8, crystal violet assays, migration and invasion ability by wound healing and transwell assays, in vivo evaluation of the anti‐neovascularisation efficacy of zebrafish and in vitro tube formation assays to detect angiogenesis, network pharmacology, Western‐blot and immunohistochemistry to analyse molecular pathways, and in vivo animal experiments on tumour progression. Key Results Our results demonstrated that the ENL and Gem combination synergistically inhibited the proliferation, migration and invasion of EOC. Tube formation and zebrafish neovascularization assays showed potent anti‐angiogenic activity of the ENL + Gem combination. In animal experiments, the combined use of ENL and Gem also synergistically inhibited tumour growth and in the meantime markedly reduced the side effects of Gem. ENL ameliorated gut dysbacteriosis of ovarian cancer animals, which significantly enhanced the synergistic anti‐cancer effect of ENL and Gem. Conclusions and Implications ENL and Gem synergistically inhibit the proliferation, migration, invasion, and angiogenesis of EOC by modulating the Akt‐Bax and Akt‐MMP9‐VEGFR‐2 pathways and ameliorating gut dysbacteriosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Genomics Research Center (Key Laboratory of Gut Microbiota and Pharmacogenomics of Heilongjiang Province, State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical Univers…
- Harbin Medical University-University of Calgary Cumming School of Medicine Centre for Infection and Genomics, Harbin Medical University, Harbin, China.
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China.
- School of Basic Medical Sciences, Harbin Medical University, Harbin, China.
- State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin, China.
- Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
ORCID profiles: Danli Cao
Funding
- Heilongjiang Postdoctoral Financial Assistance
- Merit-based Funding for Returned Overseas Students in Heilongjiang Province
- the National Natural Science Foundation of China
- Heilongjiang Provincial Natural Science Foundation
- College of Pharmacy, Harbin Medical University, Excellent Young Talents Funding
- Heilongjiang CHUNYAN Innovation Team program
- Special Fund of Harbin Medical University
- Postgraduate Research & Practice Innovation Program of Harbin Medical University
Cite
APA
Cao, D., Lin, C., Wang, J., Xu, M., Guo, Y., Yan, Y., Chai, S., Deng, S., Li, Q., Wang, X., Wang, W., Luo, L., Zhao, Y., Kang, X., Wang, S., Zhang, Y., Xu, X., Wei, J., Liu, S. L., & Liu, H. (2026). Enterolactone promotes efficacy of gemcitabine on epithelial ovarian cancer and ameliorates gut dysbacteriosis. British Journal of Pharmacology. https://doi.org/10.1111/bph.70241
Vancouver
Cao D, Lin C, Wang J, Xu M, Guo Y, Yan Y, et al. Enterolactone promotes efficacy of gemcitabine on epithelial ovarian cancer and ameliorates gut dysbacteriosis. British Journal of Pharmacology. 2026. doi:10.1111/bph.70241
BibTeX
@article{Cao2026,
author = {Cao, Danli and Lin, Caiji and Wang, Jiaxing and Xu, Mengzhi and Guo, Yi and Yan, Yu and Chai, Shuhui and Deng, Shimenghui and Li, Qinghai and Wang, Xiaoyu and Wang, Wenxue and Luo, Lingjie and Zhao, Yufan and Kang, Xin and Wang, Shuang and Zhang, Yuanyuan and Xu, Xiaohui and Wei, Jiayu and Liu, Shu-Lin and Liu, Huidi},
title = {Enterolactone promotes efficacy of gemcitabine on epithelial ovarian cancer and ameliorates gut dysbacteriosis},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70241}
}
EUVIMED